NCT06979622

Brief Summary

Transjugular intrahepatic portosystemic shunt (TIPS) is an important method for treating complications related to portal hypertension. The difficulty of its surgical procedures lies in portal vein puncture. Improper operation may lead to complications such as hepatic artery hemorrhage, hepatic capsular hemorrhage, and biliary tract hemorrhage. At present, the means of guiding portal vein puncture are limited. There is evidence supporting that ultrasound guidance can help reduce the number of punctures and lower the radiation dose, etc. However, ordinary ultrasound is limited by the influence of dimensions and can only guide punctures in the same plane, with limited guiding value. The use of the Imedis9000 magnetic navigation system can guide percutaneous vascular puncture in multiple dimensions, which can increase the success rate of puncture and shorten the operation time. This study conducted a prospective, single-arm study. The Imedis9000 magnetic navigation system was used for real-time positioning to guide precise TIPS stent implantation. The number of punctures, puncture success rate, stent implantation success rate, and the incidence of adverse events were evaluated to determine the application value of the Imedis9000 magnetic navigation system in TIPS procedure.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2025

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 13, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 20, 2025

Completed
11 days until next milestone

Study Start

First participant enrolled

May 31, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

May 20, 2025

Status Verified

May 1, 2025

Enrollment Period

4 months

First QC Date

May 13, 2025

Last Update Submit

May 13, 2025

Conditions

Keywords

TIPSElectromagneticultrasound

Outcome Measures

Primary Outcomes (1)

  • Success rate of portal vein puncture

    Puncture success rate = Number of successful cases/total number of cases ×100%.

    During TIPS procedure

Study Arms (1)

TIPS procedure under ultrasound combined with electromagnetic positioning guidance

EXPERIMENTAL
Other: ultrasound combined with electromagnetic positioning guidance

Interventions

TIPS procedure under ultrasound combined with electromagnetic positioning guidance

TIPS procedure under ultrasound combined with electromagnetic positioning guidance

Eligibility Criteria

Age18 Years+
Sexall(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age≥18 years old;
  • Including but not limited to patients requiring TIPS for: acute esophageal/gastric variceal bleeding, portal hypertensive gastropathy, cirrhotic ascites, cirrhotic hydrothorax, hepatorenal syndrome, Budd-Chiari syndrome, atypical portal hypertension, portal vein thrombosis, prevention of recurrent esophageal/gastric variceal bleeding, or prevention of recurrent ectopic variceal bleeding;
  • Deemed by clinicians to require Transjugular Intrahepatic Portosystemic Shunt (TIPS)
  • Voluntarily signed informed consent form

You may not qualify if:

  • Severe right heart failure, congestive heart failure (ejection fraction \<40%), or severe valvular heart disease;
  • Persistent severe pulmonary hypertension (mean pulmonary artery pressure \>45 mmHg) despite treatment;
  • Uncontrolled systemic infection or inflammation;
  • Hepatic encephalopathy stage III-IV;
  • Presence of cardiac pacemaker, metallic implants, or other conditions susceptible to electromagnetic interference;
  • Pregnancy or lactation;
  • Poor visualization of the portal venous system on ultrasound;
  • Investigator-determined unsuitability for study participation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypertension, Portal

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System Diseases

Central Study Contacts

Xiaofeng Zhang

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 13, 2025

First Posted

May 20, 2025

Study Start

May 31, 2025

Primary Completion

September 30, 2025

Study Completion

December 31, 2025

Last Updated

May 20, 2025

Record last verified: 2025-05